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Original article
Ambulatory blood pressure (BP) monitoring (ABPM) com-
plements clinic BP (CBP) by its ability to quantify out-of-
office BP. Several distinct BP phenotypes can be determined 
by ABPM that cannot be determined by CBP1 including the 
presence of nocturnal hypertension. In the general popula-
tion, the prevalence of nocturnal hypertension is approxi-
mately 30–45%.2,3 Prior studies suggest that nocturnal 
hypertension is associated with an increased risk of cardio-
vascular disease (CVD) events and mortality.2,4
More recently, a specific subtype of nocturnal hyperten-
sion, isolated nocturnal hypertension (INH), defined as 
nocturnal hypertension without daytime hypertension on 
ABPM, has been investigated as a CVD risk factor.3,5,6 It 
has been reported that individuals with INH may have an 
increased risk of CVD events and mortality when compared 
with individuals with daytime and nocturnal normotension 
(DNN).3,5,6 Currently, INH can only be identified using 
ABPM because its diagnosis requires the measurement of 
nighttime BP, and most individuals with INH have non-
elevated CBP.3 The confluence of increased CVD events and 
mortality risk, and a failure to be diagnosed by conventional 
clinic BP measurement, makes INH a potentially important 
ABPM phenotype.
Prior studies have shown that nocturnal hypertension 
has good short-term reproducibility.7,8 However, scarce 
data exist on the short-term reproducibility of INH. The 
reproducibility of INH has implications as to whether 
a single ABPM recording period can be used to iden-
tify this phenotype. The aim of this study was to deter-
mine the short-term reproducibility of INH on 24-hour 
ABPM among individuals not taking antihypertensive 
medications.
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BACKGROUND
Isolated nocturnal hypertension (INH), defined as nocturnal without 
daytime hypertension on ambulatory blood pressure (BP) monitoring 
(ABPM), has been observed to be associated with an increased risk of 
cardiovascular disease (CVD) events and mortality. The aim of this study 
was to determine the short-term reproducibility of INH.
METHODS
The Improving the Detection of Hypertension Study enrolled a com-
munity-based sample of adults (N = 282) in upper Manhattan without 
CVD, renal failure, or treated hypertension. Each participant completed 
two 24-hour ABPM recordings (ABPM1: first recording and ABPM2: sec-
ond recording) with a mean ± SD time interval of 33 ± 17 days between 
recordings. Daytime hypertension was defined as mean awake systolic/
diastolic BP ≥ 135/85 mm Hg; nocturnal hypertension as mean sleep 
systolic/diastolic BP ≥ 120/70 mm Hg; INH as nocturnal without day-
time hypertension; isolated daytime hypertension (IDH) as daytime 
without nocturnal hypertension; day and night hypertension (DNH) as 
daytime and nocturnal hypertension, and any ambulatory hyperten-
sion as having daytime and/or nocturnal hypertension.
RESULTS
On ABPM1, 26 (9.2%), 21 (7.4%), and 50 (17.7%) participants had 
INH, IDH, and DNH, respectively. On ABPM2, 24 (8.5%), 19 (6.7%), 
and 54 (19.1%) had INH, IDH, and DNH, respectively. The kappa sta-
tistics were 0.21 (95% confidence interval (CI) 0.04–0.38), 0.25 (95% 
CI 0.06–0.44), and 0.65 (95% CI 0.53–0.77) for INH, IDH, and DNH 
respectively; and 0.72 (95% CI 0.63–0.81) for having any ambulatory 
hypertension.
CONCLUSIONS
Our results suggest that INH and IDH are poorly reproducible 
phenotypes, and that ABPM should be primarily used to iden-
tify individuals with daytime hypertension and/or nocturnal 
hypertension.
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The Improving the Detection of Hypertension Study 
is an ongoing community-based study of adults in upper 
Manhattan designed to compare the effectiveness of dif-
ferent strategies for diagnosing ambulatory hypertension. 
Participants were recruited from the upper Manhattan com-
munity surrounding Columbia University Medical Center. 
Participants were ineligible for the study if they had any of 
the following: screening systolic CBP ≥ 160 mm Hg or dias-
tolic CBP ≥ 105 mm Hg; evidence of secondary hyperten-
sion; or were taking antihypertensive medications or other 
medications that are known to affect BP (i.e., steroids, tri-
cyclic antidepressants, etc). Participants were also excluded 
if they had a history of overt CVD, chronic kidney disease, 
liver disease, adrenal disease, thyroid disease, rheumato-
logic disease, hematologic disease, organ transplantation, 
cancer, dementia, or were pregnant. The study protocol was 
approved by the Institutional Review Board at Columbia 
University and all participants provided informed consent.
Study procedures
Information about demographics and CVD risk fac-
tors were ascertained in all enrolled participants. At the 
first visit, participants rested in the seated position for at 
least 5 minutes, after which 3 CBP readings (with at least 
1-minute intervals between readings) were performed by 
a research nurse/technician using a sphygmomanometer 
(Baum, Copiague, NY) with an appropriate-sized arm cuff 
and stethoscope. Twenty-four-hour ABPM was performed 
twice for each participant with the first ABPM recording 
period (ABPM1) occurring immediately after the first visit. 
The second ABPM recording period (ABPM2) occurred at 
a mean ± SD of 33 ± 17 days after the first recording period. 
Prior to each ABPM measurement period, participants were 
fitted with an appropriate-sized ABPM (Spacelabs Model 
90207; Snoqualmie, WA) arm cuff and a wrist actigraphy 
device (ActiWatch; Phillips Respironics, Murrayville, PA). 
Both devices were returned the next day at the conclusion of 
the 24-hour monitoring period. For each ABPM recording 
periods, BP measurements were taken at 30-minute inter-
vals throughout the 24-hour period. In the literature, the 
terms “nighttime” and “daytime” are often used interchange-
ably with “sleep” and “awake,” respectively.9 In the current 
study, the nighttime and daytime periods were defined by 
the onset of sleep and awake periods, assessed using the 
wrist actigraphy device supplemented by participant diary 
reports. Editing criteria for ABPM readings are described in 
the Supplementary Methods online.
Two-dimensional echocardiograms were performed and 
left ventricular (LV) measurements were obtained accord-
ing to the recommendations of the American Society of 
Echocardiography.10 LV mass (LVM, g) was calculated using 
the American Society of Echocardiography formula.10 LVM 
index (LVMI g/m2) was calculated by dividing LVM by esti-
mated body surface area. LV hypertrophy (LVH) was defined 
as LVMI ≥ 89 g/m2 in females and ≥ 103 g/m2 in males.10
Definitions of hypertension categories
Clinic hypertension was defined as a mean systolic CBP ≥ 
140 mm Hg or mean diastolic CBP ≥ 90 mm Hg using the 3 
CBP readings from the first visit. For each ABPM recording 
period, nocturnal hypertension was defined as mean sleep 
systolic BP ≥ 120 mm Hg or mean diastolic BP ≥ 70 mm Hg.9 
Daytime hypertension was defined as mean awake systolic 
BP ≥ 135 mm Hg or mean awake diastolic BP ≥ 85 mm Hg.9 
INH was defined as nocturnal without daytime hyperten-
sion, isolated daytime hypertension (IDH) as daytime with-
out nocturnal hypertension, day and night hypertension 
(DNH) as daytime and nocturnal hypertension, and day and 
night normotension (DNN) as the absence of both daytime 
and nocturnal hypertension. Any ambulatory hypertension 
was defined as having daytime and/or nocturnal hyper-
tension. This latter group includes INH, IDH, and DNH. 
Analyses were performed in which nocturnal hypertension, 
daytime hypertension, any ambulatory hypertension, INH, 
IDH, DNH, and DNN were defined by using systolic BP 
only and repeated using diastolic BP only, as defined in the 
Supplementary Methods. BP dipping ratio was calculated 
as mean sleep to awake systolic BP. Non-dipping status was 
defined as BP dipping ratio >0.90.9,11
Masked hypertension is defined as the absence of clinic 
hypertension but with ambulatory hypertension. In this 
study, individuals without clinic hypertension (N = 246) who 
had nocturnal hypertension were considered to have masked 
nocturnal hypertension. Among those without clinic hyper-
tension, analogous definitions were used to define masked 
daytime hypertension, any masked ambulatory hyperten-
sion, masked INH, masked IDH, masked DNH, and DNN 
without clinic hypertension, respectively.
Statistical analyses
Of the 375 participants, who were enrolled between 
March 2011 and October 2013, 85 did not have ≥80% of the 
planned ABPM readings at ABPM1 and ABPM2, leaving 
a sample size of 290 participants. Of the 290 participants, 
using the ABPM validity criteria used in the International 
Database on Ambulatory Blood Pressure in Relation to 
Cardiovascular Outcomes (IDACO),12 another 8 partici-
pants did not have 10 or more readings for awake BP and/or 
did not have 5 or more readings for sleep BP, leaving a final 
sample size of 282 participants. The mean ± SD number of 
valid readings was 45 ± 4 for ABPM1 and 45 ± 5 for ABPM2.
The reproducibility of sleep BP, awake BP, and BP dipping 
ratio was calculated using the Pearson’s correlation coef-
ficient and intraclass correlation coefficient. The reproduc-
ibility of nocturnal hypertension, daytime hypertension, 
any ambulatory hypertension, INH, IDH, DNH, DNN, and 
BP non-dipping status between ABPM1 and ABPM2 was 
assessed using the kappa (Κ) statistic and its 95% confidence 
interval (CI). The reproducibility for any ambulatory hyper-
tension is equivalent to the reproducibility for DNN.
Four sensitivity analyses were performed. First, the Κ sta-
tistic (95% CI) was calculated for nocturnal hypertension, 
daytime hypertension, any ambulatory hypertension, INH, 
IDH, DNH, and DNN defining the nighttime and daytime 
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periods using fixed time periods (12 am to 6 am for the 
nighttime period, and 10 am to 8 pm for the daytime period) 
instead of sleep and awake periods.12 Second, the analyses 
were repeated after excluding 54 participants who reported 
taking naps during the daytime period at either ABPM1 or 
ABPM2. Third, the Κ statistic (95% CI) was calculated for 
nocturnal hypertension, daytime hypertension, any ambu-
latory hypertension, INH, IDH, DNH, and DNN using 
systolic BP and diastolic BP criteria, separately, as defined 
in the Supplementary Methods. Fourth, in the 246 partici-
pants without clinic hypertension, the Κ statistic (95% CI) 
was calculated for masked nocturnal hypertension, masked 
daytime hypertension, any masked hypertension, masked 
INH, masked IDH, masked DNH, and DNN without clinic 
hypertension.
Statistical analyses were performed using SPSS v.22 
(IBM SPSS Statistics for Windows, Version 22.0; IBM, 
Armonk, NY).
RESULTS
Supplementary Table S1 shows the sample characteristics 
(n = 282) including mean BP in the clinic, and on ABPM1 
and ABPM2. Among the 282 participants, 118 (42%) were 
male, 60 (22%) were Black, and 169 (60%) were Hispanic. 
Mean ± SD age and body mass index were 39.4 ± 12.9 years 
and 27.0 ± 4.9 kg/m2, respectively. Mean ± SD LVMI 
was 79.4 ± 16.3 g/m2, and LVH was present in 12.4% of 
participants.
Of the 282 participants, 36 (12.8%) had clinic hyperten-
sion. On ABPM1, 76 (27.0%) and 71 (25.2%) participants 
had nocturnal hypertension and daytime hypertension, 
respectively. Also, 26 (9.2%), 21 (7.4%), 50 (17.7%), and 
185 (65.6%) had INH, IDH, DNH, and DNN, respectively. 
On ABPM2, 78 (27.7%) and 73 (25.9%) participants had 
nocturnal hypertension and daytime hypertension, respec-
tively. Further, 24 (8.5%), 19 (6.7%), 54 (19.1%) and 185 
(65.6%) had INH, IDH, DNH, and DNN, respectively. On 
ABPM1 and ABPM2, 90 (31.9%) and 90 (31.9%) had BP 
non-dipping respectively.
Reproducibility of sleep BP, awake BP, and BP dipping ratio
The reproducibility was excellent for awake and sleep sys-
tolic and diastolic BP levels, and moderate for BP dipping 
ratio (Supplementary Table S2).
Reproducibility of hypertension categories
Table  1 shows the cross-classification of nocturnal 
hypertension on ABPM1 and ABPM2. The reproducibil-
ity of nocturnal hypertension was good: K statistic (95% 
CI) of 0.65 (95% CI 0.55–0.76). Among participants with 
nocturnal hypertension on ABPM1 (n = 76), 58 (76.3%) 
had nocturnal hypertension on ABPM2. Among par-
ticipants without nocturnal hypertension on ABPM1 
(n = 206), 186 (90.3%) did not have nocturnal hyperten-
sion on ABPM2.
Table  2 shows the cross-classification of daytime hyper-
tension on ABPM1 and ABPM2. The reproducibility of 
daytime hypertension was good: K statistic (95% CI) of 
0.66 (95% CI 0.55–0.76). Among participants with daytime 
hypertension on ABPM1 (n = 71), 54 (76.1%) had daytime 
hypertension on ABPM2. Of participants without daytime 
hypertension on ABPM1 (n = 211), 192 (91.0%) did not have 
daytime hypertension on ABPM2.
Table 3 shows the cross-classification of any ambulatory 
hypertension on ABPM1 and ABPM2. Any ambulatory 
hypertension had good reproducibility: K statistic (95% CI) 
of 0.72 (95% CI 0.63–0.81).
Table 1. Cross-classification of nocturnal hypertension on two 24-hour ambulatory blood pressure monitoring (ABPM) recording periods
Second 24-hour ABPM (ABPM2) Reproducibility
Nocturnal hypertension No nocturnal hypertension Kappa 95% CI
First 24-hour ABPM 
(ABPM1)
Nocturnal hypertension 58 18 0.65 0.55–0.76
No nocturnal hypertension 20 186
The data are expressed as the number of participants, and kappa statistic with 95% CI. Bolded numbers represent the number of partici-
pants with concordant results across the 2 ABPM recordings. Nocturnal hypertension is defined as mean sleep systolic/diastolic blood pressure 
≥120/70 mm Hg.
Table 2. Cross-classification of daytime hypertension on two 24-hour ambulatory blood pressure monitoring (ABPM) recording periods
Second 24-hour ABPM (ABPM2) Reproducibility
Daytime hypertension No daytime hypertension Kappa 95% CI
First 24-hour ABPM 
(ABPM1)
Daytime hypertension 54 17 0.66 0.55–0.76
No daytime hypertension 19 192
The data are expressed as the number of participants, and kappa statistic with 95% CI. Bolded numbers represent the number of partici-
pants with concordant results across the 2 ABPM recordings. Daytime hypertension is defined as mean awake systolic/diastolic blood pressure 
≥135/85 mm Hg.
36 American Journal of Hypertension 29(1) January 2016
Abdalla et al.
Table 4 shows the cross-classification of INH, IDH, DNH, 
and DNN on ABPM1 and ABPM2. Among 26 participants 
with INH on ABPM1, 7 (26.9%) had INH on ABPM2, and 
18 (69.2%) of those with INH on ABPM1 had INH, IDH, or 
DNH on ABPM2. Further, 6 (28.6%) of the 21 participants 
with IDH on ABPM1 had IDH on ABPM2. There was poor 
reproducibility for INH (K statistic 0.21; 95% CI 0.04–0.38) 
and IDH (K statistic 0.25; 95% CI 0.06–0.44). Among 50 
participants with DNH on ABPM1, 37 (74.0%) had DNH 
on ABPM2. Among 185 participants with DNN on ABPM1, 
167 (90.3%) had DNN on ABPM2. Reproducibility was 
good for both DNH (K statistic 0.65; 95% CI 0.53–0.77) and 
DNN (K statistic 0.72; 95% CI 0.63–0.81).
The reproducibility was moderate for BP non-dipping 
(Supplementary Table S3) with a K statistic (95% CI) of 0.33 
(95% CI 0.21–0.45).
Sensitivity analyses
The reproducibility of ABP phenotypes using fixed time 
periods to define the nighttime and daytime periods was 
similar to the analyses for which sleep and awake periods 
were used (Supplementary Table S4). The results were also 
similar after excluding 54 participants who reported taking 
naps (Supplementary Table S5). The reproducibility of each 
BP phenotype using systolic BP criteria (Supplementary 
Table S6) and diastolic BP criteria (Supplementary Table S7) 
was examined separately. When using systolic vs. diastolic 
BP criteria, the reproducibility of INH was lower, whereas 
the reproducibility of IDH increased. Finally, among the 246 
participants without clinic hypertension, the reproducibility 
of masked nocturnal hypertension, masked daytime hyper-
tension, any masked hypertension, masked INH, masked 
IDH, masked DNH, and DNN without clinic hypertension 
was similar to the reproducibility of the corresponding BP 
categories in the entire sample (Supplementary Table S8).
DISCUSSION
Our primary finding is that INH has poor short-term 
reproducibility. In contrast, nocturnal hypertension, day-
time hypertension, and DNH were reproducible pheno-
types. Our study, which to our knowledge is among the first 
to report the short-term reproducibility of INH, suggests 
that a single 24-hour ABPM period should not be used to 
identify individuals with INH.
Nocturnal hypertension is associated with an increased 
risk of target organ damage, CVD outcomes, and mortality, 
independent of daytime BP.2–4,11,13 INH may be an important 
subtype of nocturnal hypertension, as several studies have 
shown that it is associated with an increased risk of subclini-
cal CVD, CVD events, and mortality.2,3,5,14–16 In a popula-
tion study of 677 Chinese participants, those with INH vs. 
with DNN had elevated indices of arterial stiffness including 
central and peripheral augmentation indexes, ambulatory 
arterial stiffness index, and brachial-ankle pulse wave veloc-
ity.3 Of the participants with INH, 95.6% did not have clinic 
hypertension.3 In an analysis of 11 population-based cohorts 
that included 8,711 participants from Asia, Europe, and 
South America, Fan et al. showed that INH was associated 
with an increased risk of CVD events (heart rate (HR) 1.38, 
95% CI 1.02–1.87) and all-cause mortality (HR 1.29, 95% CI 
Table 4. Cross-classification of ambulatory blood pressure categories based on nocturnal and daytime hypertension on two 24-hour 
ambulatory blood pressure monitoring (ABPM) recording periods
Second 24-hour ABPM (ABPM2) Reproducibility
INH IDH DNH DNN Kappa 95% CI
First 24-hour ABPM (ABPM1) INH 7 2 9 8 INH: 0.21 0.04–0.38
IDH 2 6 7 6 IDH: 0.25 0.06–0.44
DNH 5 4 37 4 DNH: 0.65 0.53–0.77
DNN 10 7 1 167 DNN: 0.72 0.63–0.81
The data are expressed as the number of participants, and kappa statistic with 95% CI. Bolded numbers represent the number of participants 
who were classified in the same category across the 2 ABPM recordings.
Abbreviations: DNH, daytime and nighttime hypertension; DNN, daytime and nighttime normotension; IDH, isolated daytime hypertension; 
INH, isolated nocturnal hypertension.
Table 3. Cross-classification of any ambulatory hypertension on two 24-hour ambulatory blood pressure monitoring (ABPM) recording 
periods
Second 24-hour ABPM (ABPM2) Reproducibility
Ambulatory hypertension No ambulatory hypertension Kappa 95% CI
First 24-hour ABPM 
(ABPM1)
Ambulatory hypertension 79 18 0.72 0.63–0.81
No ambulatory hypertension 18 167
The data are expressed as the number of participants, and kappa statistic with 95% CI. Bolded numbers represent the number of participants 
with concordant results across the 2 ABPM recordings. Any ambulatory hypertension is defined as daytime hypertension (mean awake systolic/
diastolic BP ≥135/85 mm Hg) and/or nocturnal hypertension (mean sleep systolic/diastolic BP ≥120/70 mm Hg).
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1.01–1.65) when compared with DNN.2 In this study, 79.2% 
of the individuals with INH did not have clinic hyperten-
sion. Finally, in a recent study of 4,608 treated patients with a 
history of hypertension but who were controlled in the clinic 
(<140/90 mm Hg), the prevalence of INH was greater than 
the prevalence of IDH (24.3% vs. 12.9%, respectively).17 The 
results of these studies suggest that occult hypertension that 
only occurs at night and is not seen in the daytime period is 
associated with increased CVD risk.
Hermida et  al.18 demonstrated that individuals with 
hypertension (N = 3,444) randomized to nighttime admin-
istration of antihypertensive therapy had significantly lower 
mean nighttime BP, higher BP decline, reduced prevalence of 
non-dipping, and a lower risk of CVD events than individu-
als randomized to morning administration of antihyperten-
sive therapy. Further, lower nighttime BP, associated with 
antihypertensive medications given at night vs. morning, 
was associated with a lower risk of CVD events, independ-
ent of changes in daytime BP.18 Whether the cardiovascu-
lar benefits of nighttime administration of antihypertensive 
therapy extends to those with INH remains unknown. The 
poor reproducibility of INH, as demonstrated in our study, 
suggests, however, that INH may not be a clinically useful 
treatment target.
Because ABPM remains the gold standard for diagnosing 
nocturnal hypertension, characterizing the reproducibility 
of INH is essential for determining whether individuals in 
clinical practice should be further characterized as having 
INH. Studies examining the reproducibility of INH, how-
ever, are scarce.19 The long-term stability of INH was pre-
viously studied in 30 Chinese participants who underwent 
repeat 24-hour ABPM at a mean follow-up of 3.5  years.3 
Among these participants, 10 (33.3%) had INH at follow-up, 
whereas 10 (33.3%), 2 (6.7%), and 8 (26.7%) were reclassi-
fied as having DNH, IDH, and DNN respectively. Whether 
these results represent the natural history of INH or might 
be explained by a change in risk factors associated with INH 
over a long follow-up period is unclear. The current study, 
which fills an important knowledge gap, indicates that the 
diagnosis of INH using a single 24-hour ABPM recording 
period has low short-term reproducibility.
The results of our study also indicate that sleep and awake 
BP had high reproducibility for both systolic and diastolic 
BP. These findings are similar to Eguchi et al. who demon-
strated that sleep and awake BP had good reproducibility 
among 42 individuals with hypertension who underwent 
repeat ABPM twice within a 2-week period during an 
observation period without antihypertensive medication.20 
Further, in our study, the short-term reproducibility of noc-
turnal hypertension and daytime hypertension were both 
good, which is similar to prior studies.21–23 Since the repro-
ducibility of INH and separately IDH depends on the repro-
ducibility of both nocturnal and daytime hypertension, the 
low short-term reproducibility of INH and IDH, as observed 
in our study, is not surprising.
In the current study, the reproducibility of any ambula-
tory hypertension was good. Given that prior studies have 
shown that daytime hypertension, nocturnal hypertension, 
and DNH are each associated with an increased risk of CVD 
events,2,24 it may be more advantageous to use ABPM to 
diagnose any form of ambulatory hypertension, without fur-
ther classifying individuals into having INH or IDH. In our 
study, 69.2% of those with INH on ABPM1 were classified as 
having INH, IDH, or DNH (i.e., any ambulatory hyperten-
sion) on ABPM2. This may explain why INH determined on 
a single ABPM is associated with an increased risk of CVD 
and mortality3,5 even though the reproducibility of INH 
is low.
Finally, the prevalence of INH in our study was 9.2% on 
ABPM1 and 8.5% on ABPM2. This prevalence is similar 
to the prevalence of INH reported in prior studies (6.0–
10.9%),3,19 which used a single ABPM recording period 
to identify INH. Given that INH has low reproducibility, 
repeat 24-hour ABPM is needed to identify individuals who 
have INH on both ABPM recording periods. However, the 
prevalence of INH on both recording periods was only 2.5% 
(7/282), suggesting that it may not be efficient to screen indi-
viduals for INH.
A major strength of this study is that the sample popula-
tion was community-based and had high minority represen-
tation of Hispanics and African-Americans. Additionally, 
our study included participants who underwent repeat 
ABPM within a short interval, allowing us to determine the 
short-term reproducibility of several BP categories.
Our study has several possible limitations. First, our analy-
sis may be limited by the relatively small sample size. Second, 
our findings may not be generalizable to other populations 
as our study did not include a high proportion of individuals 
with diabetes, and individuals with chronic kidney disease 
were excluded. The reproducibility of INH in populations 
enriched with individuals with diabetes and/or chronic kid-
ney disease requires further evaluation. Additionally, infor-
mation regarding nocturia or other reasons for awakening 
at night, which may impact nighttime BP, was not collected. 
Lastly, our findings may also not be generalizable to hyper-
tensive patients taking antihypertensive medications.
In conclusion, our findings suggest that INH is poorly 
reproducible and not a stable phenomenon over the short 
term. Similar poor reproducibility was found for IDH. In 
contrast, daytime, nighttime, and any ambulatory hyperten-
sion had high reproducibility. These findings have important 
implications for the risk stratification of individuals using 
a single 24-hour ABPM recording period. Our results sug-
gest that a single 24-hour ABPM reporting period should be 
primarily used to identify individuals with daytime hyper-
tension and/or nocturnal hypertension, without further 
classifying individuals into having isolated forms of ambula-
tory hypertension including INH and IDH. Our study adds 
to the growing literature as to how 24-hour ABPM should 
be used to risk stratify individuals for hypertension-related 
outcomes.
SUPPLEMENTARY MATERIALS
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
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